Somatropin Injection
Brand names: Norditropin
Category: Endocrinology/Metabolism
FDA status: To Be Discontinued · Last FDA update: Nov 14, 2025 · First posted: Nov 14, 2025 · 1 manufacturers, 1 listed presentations
As of Nov 14, 2025, the FDA lists Somatropin Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) NDC 0169-7703-21 |
Novo Nordisk, Inc. | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Endocrinology/Metabolism medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Somatropin Injection (FDA data as of Nov 14, 2025). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Somatropin Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/somatropin-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).